Gilead Sciences, Inc.(GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Latest News & Analysis
Gilead's Cell Therapy Vindication Collides with Broader Oncology Execution Risk
ASH 2025 validates cell therapy but Trodelvy's breast cancer failure signals execution risk across Gilead's portfolio.
ASH 2025 Validates Gilead's Cell Therapy as HIV Pricing Offset
ASH 2025 abstracts validate Gilead's cell therapy transformation with Yescarta durability, anito-cel safety, offsetting activist HIV pricing constraints.
Gilead Proves Activist Pressure Manageable Through Volume Momentum, Portfolio Validation
Gilead's Q3 beat and Yeztugo award show the company can sustain growth despite activist pricing constraints through volume momentum.
Activist Victory Constrains Gilead's Margin Expansion Thesis
AHF-led coalition forces Gilead to abandon price hikes, eliminating pricing optionality that underpinned earnings growth strategy.
Gilead Q3 Earnings Preview: HIV Resilience Masks Cell Therapy Execution Risk
Wall Street expects Gilead Q3 earnings of $2.15 per share, but analyst consensus darkens as Tecartus underperforms and HCV declines threaten revenue stability.
Gilead's Lenacapavir: FDA Approval Could Revolutionize HIV Prevention
Gilead Sciences update highlights lenacapavir FDA NDA acceptance, strong Q4 earnings, and pipeline growth.
Gilead's Lenacapavir: FDA Approval Looms Amid Robust Earnings
Gilead Sciences' latest update highlights FDA priority review for Lenacapavir and strong Q4 earnings, underscoring its leadership in HIV prevention.
Gilead Sciences: Pipeline Progress, Regulatory Wins, and Strategic Outlook for 2025
Gilead Sciences navigates regulatory milestones, pipeline adjustments, and strategic priorities, impacting its market position and future growth. A comprehensive intraday update.
Gilead's HIV Strategy: Lenacapavir & Seladelpar Milestones
Gilead Sciences advances with FDA review for Lenacapavir and EU approval for Seladelpar, boosting growth prospects.
Gilead Sciences: Lenacapavir, Seladelpar, and Future Biopharma
Gilead Sciences navigates regulatory milestones with Lenacapavir and Seladelpar, faces Medicare reforms, and prepares for investor conferences. Innovation and strategic expansion are key.
Gilead Sciences: FDA Approval, European Expansion, and Q4 2024
Gilead Sciences sees a resurgence with FDA priority review for Lenacapavir, European approval for Seladelpar, and strong Q4 2024 results, signaling strategic growth.
Gilead Sciences (GILD): HIV, Oncology, and European Expansion
Gilead Sciences (GILD) navigates a dynamic landscape, leveraging its HIV dominance while expanding in oncology and Europe. Approvals signal growth, but a high P/E requires caution.
Gilead Sciences (GILD): Intraday Snapshot & Corporate Updates
On March 5, 2025, Gilead Sciences (GILD) displayed steady intraday performance amid key regulatory, financial, and strategic developments.
Gilead Sciences (GILD): A Deep Dive into HIV, Liver Disease, and Oncology Growth
Gilead Sciences (GILD) navigates growth in HIV, liver disease, and oncology, driven by key products and strategic collaborations. Lenacapavir and Seladelpar offer market expansion.
Gilead Sciences (GILD): Stock Analysis, Revenue Drivers, and Future Outlook
Analysis of Gilead Sciences (GILD): recent market performance, revenue drivers like Biktarvy and lenacapavir, financial health, and future growth opportunities.
Gilead Sciences: Lenacapavir, HIV Advancements, and Market Impact [GILD]
Analysis of Gilead Sciences' HIV advancements, lenacapavir's market impact, and strategic outlook amid healthcare policy changes. A comprehensive report for investors.
Gilead Sciences: Lenacapavir's Promise and Financial Outlook
Gilead Sciences navigates Lenacapavir's promise, regulatory hurdles, and financial outlook. Key insights on cash flow, dividends, and healthcare policy impacts.
Gilead Sciences (GILD): HIV Funding Cuts, Lenacapavir, and Stock Analysis
Gilead Sciences (GILD) faces HIV funding concerns amid lenacapavir advancements. Analysis of stock performance, competition, and future strategies for investors.
Gilead Sciences (GILD): HIV Funding Cuts and Pipeline Analysis
Gilead Sciences (GILD) navigates potential HIV funding cuts. A look at the impact on Biktarvy, Descovy, lenacapavir, and the company's diversified pipeline.
Gilead Sciences: HIV Funding Cuts, Livdelzi Approval, and SUNLENCA's Potential
Gilead Sciences navigates HIV funding cuts, balancing risks with growth from SUNLENCA and LIVDELZI. Key financial metrics and strategic implications analyzed.
Gilead Sciences (GILD): Navigating HIV Funding Cuts with Livdelzi and SUNLENCA
Gilead Sciences (GILD) navigates HIV funding cuts with Livdelzi and SUNLENCA. Analyst ratings are mixed, and diversification into oncology and liver disease is crucial.
Gilead Sciences: Analyst Upgrades, Tariff Risks, and HIV Market Dynamics
Gilead Sciences navigates analyst upgrades, tariff risks, HIV funding concerns, and Livdelzi's European approval, strategically positioned for growth amidst challenges.
Gilead Sciences (GILD) Financials and Strategic Priorities Ahead of Q1 Earnings
Analyzing Gilead Sciences' financial trends and strategic focus ahead of its Q1 2025 earnings report, highlighting key pipeline progress and market dynamics.
Gilead Sciences: Analyzing Recent Financials and Pipeline Catalysts
Gilead Sciences navigates a shifting landscape marked by significant pipeline advancements, particularly with Trodelvy and CAR-T therapies, alongside notable shifts in profitability.
Gilead Sciences ([GILD](/dashboard/companies/GILD)): Clinical Hold, Legal Clouds, & Pipeline Resilience
Gilead Sciences faces an FDA clinical hold on HIV trials and legal scrutiny, impacting its stock and pipeline, but its core business remains robust.
Gilead Sciences (GILD): Clinical Hold, Legal Scrutiny, and Key Catalysts
Gilead (GILD) faces an FDA clinical hold on HIV trials and securities investigations. We dive into the market impact and the pivotal lenacapavir decision.
Gilead Sciences (GILD): Clinical Hold, Legal Battles, & Strategic Pivot
Gilead Sciences faces a partial FDA clinical hold on its HIV treatment, GS-4500, alongside ongoing legal challenges, impacting short-term outlook.
Gilead Sciences (GILD) Faces FDA Holds & Legal Risks in 2025
Comprehensive analysis of Gilead Sciences' recent regulatory and legal challenges, including FDA clinical holds on HIV treatments and securities investigations, and their impact on financial outlook and stock performance in 2025.
Gilead Sciences' YezTugo Approval Transforms HIV Prevention, Amidst Legal Scrutiny
Gilead Sciences' [GILD](/dashboard/companies/GILD) recent FDA approval of YezTugo (Lenacapavir) marks a paradigm shift in HIV prevention, offering a twice-yearly injectable.
Gilead Sciences (GILD): Yeztugo's Breakthrough vs. Pipeline Risks
Gilead Sciences navigates a complex period with Yeztugo's launch for HIV prevention contrasting sharply with clinical holds on key pipeline drugs.
Gilead HIV Trial Hold: Balancing Yeztugo's Triumph with Next-Gen Safety Concerns and Investor Scrutiny
Gilead Sciences faces a dual reality: historic HIV prevention approval with Yeztugo, contrasted with clinical holds on next-gen drugs and legal probes.
Gilead Sciences Inc. (GILD) Latest Financial and Strategic Update | Market Analysis
Explore Gilead Sciences' recent financial performance, FDA clinical hold impact, and strategic outlook with detailed data-driven insights for investors.
Gilead Sciences Latest Legal Challenges and Financial Performance Insights - Monexa AI
Explore Gilead Sciences' recent legal challenges, earnings trends, and strategic impacts on its financial health and investor outlook.
Gilead Sciences HIV Growth and Financial Analysis Amidst Legal and Market Dynamics | Monexa AI
Explore Gilead Sciences' recent HIV drug advancements, financial shifts, legal challenges, and competitive positioning shaping its growth outlook and investor strategy.
Gilead Sciences Latest Developments: Lenacapavir Access Strategy and Financial Overview
Gilead Sciences advances HIV prevention with lenacapavir Global Fund deal amid pricing debates and solid financials, reinforcing its market leadership.
Gilead Sciences (GILD) Market Analysis: Strategic HIV Prevention Partnership and Financial Performance Insights
Gilead Sciences advances HIV prevention globally with a key partnership and faces financial challenges, impacting its market positioning and future growth.
Gilead Sciences, Inc. Latest Corporate and Financial Update Analysis
Comprehensive analysis of Gilead Sciences' recent financial performance, strategic moves, and market positioning impacting investor decisions.
Gilead Sciences: Lenacapavir Advances HIV Prevention Amid Mixed Financial Signals
Gilead Sciences leads HIV prevention with lenacapavir's twice-yearly injection, navigating financial challenges and market competition in 2025.
Gilead Sciences Latest Developments: Legal Challenges and Lenacapavir's Market Impact
Gilead Sciences faces a securities fraud investigation amid promising HIV drug lenacapavir's WHO endorsement, impacting investor confidence and future growth.
Gilead Sciences, Inc. Latest Developments and Financial Analysis: Lenacapavir, Legal Challenges, and Market Position
Explore Gilead Sciences' recent strides with lenacapavir, legal scrutiny, financial health, and strategic positioning in the evolving HIV treatment landscape.
Gilead Sciences: Navigating FDA Hold Amidst Key Lenacapavir Decision
Gilead Sciences faces regulatory hurdles with an FDA clinical hold on HIV trials, while awaiting a key decision on lenacapavir for PrEP. We analyze the market impact and financial health.
Gilead Sciences, Inc. Deep Dive: Regulatory Challenges and Strategic Growth in HIV Prevention
Explore Gilead Sciences' latest regulatory hurdles, financial performance, and strategic advances in HIV prevention with Lenacapavir shaping future growth prospects.
Gilead Sciences Inc. Latest Analysis: Navigating Regulatory Hurdles & Lenacapavir's Market Impact
Explore Gilead Sciences' recent regulatory challenges, $202M settlement, Lenacapavir's FDA approval, and their effects on financials and stock performance.
Gilead Sciences Latest Financial and Strategic Update Amid Drug Pricing Pressures
Gilead Sciences navigates significant drug pricing pressures with strategic pivots, impacting financials and future growth, anchored by Lenacapavir's potential.
Gilead Sciences Q2 2025 Analysis: HIV Franchise Resilience, Lenacapavir Launch, and Pricing Pressure Impact
Gilead Sciences faces flat HIV revenue due to Medicare reforms but gains growth from Lenacapavir launch; navigating pricing pressures amid strong fundamentals.
Gilead Sciences Q2 2025 Analysis: Yeztugo Launch, HIV Franchise Growth, and Litigation Impact
Gilead Sciences surges on Q2 2025 earnings fueled by Yeztugo's HIV prevention success, robust HIV drug sales, and strategic oncology expansion amid manageable litigation risks.
Gilead Sciences: Cashflow Strength Masks a 2024 Earnings Collapse — What Investors Should Watch
Gilead reported **$28.75B** revenue in FY2024 but **net income plunged -91.53% to $480M** while free cash flow rose to **$10.3B** — a divergence that defines 2025 risks.
Gilead Sciences (GILD): Payer Shock, Cell‑Therapy Push and a Cash‑Rich Reset
CVS exclusion of Yeztugo and Kite’s acquisition reshuffle Gilead’s growth path; FY2024 showed **$28.75B revenue** but **net income plunged to $480MM** amid acquisitions and charges.
Gilead Sciences: Yeytuo Approval, Cash-Flow Strength and the 2024 Profit Shock
EU approval for lenacapavir (Yeytuo) meets payer resistance in the U.S.; Gilead shows **$10.3B free cash flow (2024)** amid a **-91.54%** net income drop that reshapes near-term earnings dynamics.
Gilead Sciences (GILD) Financial Analysis: Clinical Wins Amidst Profit Shifts
Gilead Sciences navigates clinical successes in oncology, including promising Trodelvy and CAR-T data, amidst a sharp decline in 2024 net income.
Gilead Sciences (GILD): Lenacapavir Scale-Up and a Cash-Rich, Earnings-Light 2024
Gilead pledged Lenacapavir at-cost to PEPFAR for up to two million people while FY2024 GAAP net income plunged to **$480MM** even as operating cash flow reached **$10.83B**.
Gilead Sciences (GILD): Cash-Rich but Profits Squeezed — The Lenacapavir Growth Pivot
Gilead posted **$28.75B** revenue in FY2024 but **net income collapsed to $480MM** while free cash flow surged to **$10.3B**—a tension between cash strength and GAAP profits.